Global Blood Therapeutics, Inc.
GBT was delisted on the 4th of October, 2022.
84 hedge funds and large institutions have $488M invested in Global Blood Therapeutics, Inc. in 2016 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 38 increasing their positions, 19 reducing their positions, and 24 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 19
26% more capital invested
Capital invested by funds: $389M → $488M (+$99.9M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
10% less funds holding
Funds holding: 93 → 84 (-9)
11% less call options, than puts
Call options by funds: $5.29M | Put options by funds: $5.97M
38% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$10.4M |
| 2 |
IHM
Iguana Healthcare Management
New York
|
+$6.67M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$4.37M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.73M |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$3.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$29.8M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$17.1M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$4.84M |
| 4 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$4.47M |
| 5 |
Jennison Associates
New York
|
-$3.94M |
GBT Hedge Fund Activity: Q3 2016 in Review
84 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q3 2016, worth a combined $488M — up 26% from $389M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of GBT and 15 opened new positions — a net loss of 9 holders — while 19 trimmed existing stakes and 38 added.
The largest buyer was Wellington Management Group, adding an estimated $10.4M. The largest seller was Deerfield Management, cutting an estimated $29.8M.
- 84 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q3 2016, down from 93 in Q2 2016.
- Funds reported $488M of Global Blood Therapeutics, Inc. stock for Q3 2016, up 26% quarter-over-quarter.
- 15 funds opened new Global Blood Therapeutics, Inc. positions in Q3 2016 and 24 closed out, a net change of -9 holders.
- The largest Global Blood Therapeutics, Inc. buyer in Q3 2016 was Wellington Management Group, an estimated $10.4M added.
- The largest Global Blood Therapeutics, Inc. seller in Q3 2016 was Deerfield Management, an estimated $29.8M sold.
Based on aggregated 13F filings for Q3 2016.